Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers.

Trial Profile

A phase I trial of first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Claudin 18.2 CAR T cell therapy (Primary)
  • Indications Gastric cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2018 Results published in the CARsgen Media Release
    • 07 Sep 2018 According to a CARsgen media release, data from this trial were presented at 2018 CAR-TCR Summit.
    • 12 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top